ArticleBioMed research international2016
Advanced Glycation End Products Induce Obesity and Hepatosteatosis in CD-1 Wild-Type Mice.
Article in BioMed research international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 56 citations in OpenAlex.
- Construction and evaluation of a diagnostic model for metabolic dysfunction-associated steatotic liver disease based on advanced glycation end products and their receptors.Frontiers in medicine · 2025Article
- The relationship between advanced glycation end products, metabolic metrics, HbAFrontiers in endocrinology · 2025Article
- Liquid Chromatography with Tandem Mass Spectrometry Analysis of Carboxymethyl Lysine in Indonesian Foods.Molecules (Basel, Switzerland) · 2024Article
- Increased dietary intake of ultraprocessed foods and mitochondrial metabolism alterations in pediatric obesity.Scientific reports · 2023Article
- Association between diabetes and cancer. Current mechanistic insights into the association and future challenges.Molecular and cellular biochemistry · 2023Review
- Exercise Restores Hypothalamic Health in Obesity by Reshaping the Inflammatory Network.Antioxidants (Basel, Switzerland) · 2023Review
- Artemisia alleviates AGE-induced liver complications via MAPK and RAGE signaling pathways modulation: a combinatorial study.Molecular and cellular biochemistry · 2022Article
- Simvastatin Improves Microcirculatory Function in Nonalcoholic Fatty Liver Disease and Downregulates Oxidative and ALE-RAGE Stress.Nutrients · 2022Article
- Advanced glycation end product: A potential biomarker for risk stratification of non-alcoholic fatty liver disease in ELSA-Brasil study.World journal of gastroenterology · 2021Article
- Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy.Free radical biology & medicine · 2021Review
- Contribution of RAGE axis activation to the association between metabolic syndrome and cancer.Molecular and cellular biochemistry · 2021Review
- Physiological and metabolomic consequences of reduced expression of the Drosophila brummer triglyceride Lipase.PloS one · 2021Article
- Dietary intake of advanced glycation end products (AGEs) and changes in body weight in European adults.European journal of nutrition · 2020Article
- LSEC model of aging.Aging · 2020Article
- Advanced Glycation End Products: Building on the Concept of the "Common Soil" in Metabolic Disease.Endocrinology · 2020Review
- Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products.International journal of molecular sciences · 2019Review
- Life-style-induced metabolic derangement and epigenetic changes promote diabetes and oxidative stress leading to NASH and atherosclerosis severity.Journal of diabetes and metabolic disorders · 2018Article
- The Role of Advanced Glycation End Products in Aging and Metabolic Diseases: Bridging Association and Causality.Cell metabolism · 2018Review
- Advanced Glycation End Products in the Pathogenesis of Psoriasis.International journal of molecular sciences · 2017Review
- Hepatic microvascular dysfunction and increased advanced glycation end products are components of non-alcoholic fatty liver disease.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
AGEs are a heterogeneous group of molecules formed from the nonenzymatic reaction of reducing sugars with free amino groups of proteins, lipids, and/or nucleic acids. AGEs have been shown to play a role in various conditions including cardiovascular disease and diabetes. In this study, we hypothesized that AGEs play a role in the "multiple hit hypothesis" of nonalcoholic fatty liver disease (NAFLD) and contribute to the pathogenesis of hepatosteatosis. We measured the effects of various mouse chows containing high or low AGE in the presence of high or low fat content on mouse weight and epididymal fat pads. We also measured the effects of these chows on the inflammatory response by measuring cytokine levels and myeloperoxidase activity levels on liver supernatants. We observed significant differences in weight gain and epididymal fat pad weights in the high AGE-high fat (HAGE-HF) versus the other groups. Leptin, TNF-α, IL-6, and myeloperoxidase (MPO) levels were significantly higher in the HAGE-HF group. We conclude that a diet containing high AGEs in the presence of high fat induces weight gain and hepatosteatosis in CD-1 mice. This may represent a model to study the role of AGEs in the pathogenesis of hepatosteatosis and steatohepatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.